Press Release

Digbi Health in the news

Featured Press

pin

Digbi Health Launches an SEC-regulated Offering, Giving Millions the Opportunity to Invest in Groundbreaking Genetics and Gut Microbiome-based Care for Obesity and Digestive Health

Palo Alto, California, September 30, 2024 - Digbi Health, a leader in Precision Biology-based care for obesity, type 2 diabetes, and gastrointestinal health, is excited to announce its SEC-regulated raise. This initiative allows millions to invest in the company's mission to transform healthcare by expanding access to personalized, genetics-based, and gut microbiome-driven treatments. Opening Equity Participation and Expanding Access to Care For the first time, Digbi Health is offering equity participation to the public, democratizing an investment opportunity that was previously only available to venture capital firms. This SEC-regulated raise allows individuals to support Digbi Health's vision of making Precision Biology-driven care for obesity and digestive health accessible to millions by expanding insurance benefits and Medicare coverage. "By offering investment opportunity to the public, we are not only expanding ownership but also accelerating our commitment to making Precision Biology treatments available to millions," said Ranjan Sinha, CEO of Digbi Health. "Our goal is to integrate personalized, genetics and microbiome-based programs into everyday healthcare, expanding coverage through insurance and Medicare so more people can benefit from advanced, data-driven care." Transforming Health Care Through Innovation Thirty-five million users already have access to Digbi Health's personalized programs through major health plans and employers. With over $16 million in funding from leading venture capital firms, the company will further expand its reach. This Reg CF offering on StartEngine allows more individuals to support the company's groundbreaking work in bringing effective, personalized treatments for obesity and digestive health to millions. About Digbi Health Digbi Health pioneered Precision Biology, integrating gut microbiome, CGM, and genetics to holistically prevent and treat three of the top four most expensive healthcare conditions - Obesity, Cardiometabolic, and Digestive. Our innovative, proven approach is highly differentiated and resonates with employers and health plans seeking new ways to eliminate the scourge of point solutions and reduce healthcare costs, especially GLP-1-related drug costs. Our competitive edge lies in our unique data and bioinformatics platform, consolidating millions of diverse data points across genetics, progression of gut microbiome, metabolic, health, and disease markers. This repository empowers us to personalize care, unearth patentable signatures, generate impactful health risk profiles, and stratify patient care accurately for treatment. Digbi's unique contactable data set appeals to top pharmaceutical and food companies, positioning us as a leader in the field. This equity raise is being conducted in accordance with Regulation Crowdfunding (Reg CF), a provision enacted by Congress under the JOBS Act, and is fully compliant with the rules and regulations established by the U.S. Securities and Exchange Commission (SEC). For more information on the equity raise and how to invest, visit https://www.startengine.com/offering/digbi-health

Aniiket Sengar
30 September, 2024
pin

Digbi Health Expands Its Employer Offering with the GLP-1 Obesity Management Solution Integrated Across Payer, PBM, Provider, and Employer

News Provided by Digbi Health July 22 2024 10:00 EST State Public Health Insurance Trust Partners with Digbi Health to Manage Obesity Treatment Costs Amid Rising GLP-1 Drug Expenses for its Municipal and Teachers Union Workers Mountain View, July 22, 2024 – A leading public health insurance trust has selected Digbi Health to manage the escalating costs and effective utilization of new GLP-1 weight-loss drugs. This partnership will leverage Digbi Health's proprietary Obesity Compass to provide effective and cost-efficient treatment plans for all its members. Due to the surge in demand for GLP-1 drugs, employers and health plans nationwide face uncertainty and significant cost increases. This partnership addresses these challenges by employing innovative solutions without compromising a member’s health. Key Highlights: Effective Cost Management:The initiative launched in June as a cost-containment strategy after unsustainable growth in GLP-1 medication usage and costs. Prior Authorization:Digbi Health will oversee the Prior Authorization for all weight management medications, using patented predictive modeling to determine the most effective and economical care modalities for members to achieve a healthy BMI. Holistic Solution: Digbi Health leverages genetics, gut microbiome, continuous glucose monitoring (CGM), and lab reports to provide personalized food and lifestyle support to all members on weight management medications. This approach addresses the underlying root causes of their conditions, related comorbidities, medication side effects, and, if recommended, medication tapering. Precision Biology is an innovative approach that uses an individual's genetic makeup, gut microbiome profile, and metabolic data to create highly personalized treatment plans. Precision Biology can identify the most effective dietary, lifestyle, and pharmacological interventions by analyzing a person's unique biological data. This method ensures that treatments are tailored to address the root causes of obesity and related conditions, resulting in more effective and sustainable health outcomes. “As the market struggles with finding an optimal strategy for weight management and GLP-1 cost containment, we aim to set new care standards by focusing on three key areas: enhancing member experiences through integrations, using Precision Biology to more accurately identify those who need medication support, and tackling the underlying root causes, comorbidities, and side effects. We look forward to successfully collaborating with employers, health plans, benefits consultants, and PBMs to deliver personalized, effective, and affordable care,” said Ranjan Sinha, Founder and CEO of Digbi Health. About Digbi Health: Digbi Health pioneered Precision Biology to treat obesity, T2 Diabetes, and digestive health by harnessing genetics and gut microbiome analysis. This innovative approach develops personalized "Food-As-Medicine" treatment plans, targeting the root causes of obesity and T2D. Digbi Health’s GLP Compass, developed working with Novo Nordisk and the University of Virginia Medical School, uses proprietary data and AI models to identify the most clinically effective and cost-efficient treatment paths.

Aniiket Sengar
21 July, 2024
pin

Gulf Coast Regional Blood Center selects Digbi Health to Elevate Employee Health Programs for Weight Management, Diabetes, and Digestive Issues

Palo Alto, California, Feb 15, 2024 - Digbi Health, an innovator in personalized health technology, is proud to announce its new collaboration with Gulf Coast Regional Blood Center, a key blood provider in Houston and surrounding counties. This partnership is set to revolutionize employee health management by integrating personalized health solutions based on advanced genetics and gut biome analysis into the wellness programs of a critical healthcare provider. Enhancing Employee Wellness at Gulf Coast Regional Blood Center The Gulf Coast Regional Blood Center team will benefit from Digbi Health's comprehensive health platform to optimize weight management and mitigate physical and mental health challenges. By leveraging precision biology through detailed genetics and gut microbiome analysis, this initiative perfectly aligns with the center's dedication to fostering the health and well-being of its employees and the communities they serve. The program specifically addresses chronic conditions such as obesity, type 2 diabetes, and digestive disorders, benefiting employees and their families. A Strategic Collaboration to Enhance Community Health Digbi Health's tailored health approach is strategically aligned with the Gulf Coast Regional Blood Center’s core mission of community partnership to save and sustain lives, beginning with its workforce. This collaboration is poised to enrich the center's employee wellness program, establishing a new benchmark for employee care within the life-saving operations of the blood center. Ranjan Sinha, CEO of Digbi Health, said on the collaboration, "This partnership is a milestone for us at Digbi Health. It embodies our commitment to transform individual chronic care by decoding our genetics, gut biome, and blood markers.“ About Gulf Coast Regional Blood Center Founded in 1975, Gulf Coast Regional Blood Center is an independent, nonprofit organization committed to ensuring a safe and reliable blood supply. With over 650 employees, Gulf Coast Regional Blood Center serves a vast area across Texas, including 26 counties. About Digbi Health Digbi Health specializes in genetics, gut microbiome, and digital health technologies to redefine personalized healthcare. Their platform is designed to reduce medication dependence and healthcare costs, particularly in chronic illness management. For more information, media inquiries, or interviews, please contact: partner@digbihealth.com This contract underscores Digbi Health's commitment to expanding personalized healthcare nationwide.

Aniiket Sengar
15 March, 2024

Latest Press

Digbi Health Launches an SEC-regulated Offering, Giving Millions the Opportunity to Invest in Groundbreaking Genetics and Gut Microbiome-based Care for Obesity and Digestive Health

Palo Alto, California, September 30, 2024 - Digbi Health, a leader in Precision Biology-based care for obesity, type 2 diabetes, and gastrointestinal health, is excited to announce its SEC-regulated raise. This initiative allows millions to invest in the company's mission to transform healthcare by expanding access to personalized, genetics-based, and gut microbiome-driven treatments. Opening Equity Participation and Expanding Access to Care For the first time, Digbi Health is offering equity participation to the public, democratizing an investment opportunity that was previously only available to venture capital firms. This SEC-regulated raise allows individuals to support Digbi Health's vision of making Precision Biology-driven care for obesity and digestive health accessible to millions by expanding insurance benefits and Medicare coverage. "By offering investment opportunity to the public, we are not only expanding ownership but also accelerating our commitment to making Precision Biology treatments available to millions," said Ranjan Sinha, CEO of Digbi Health. "Our goal is to integrate personalized, genetics and microbiome-based programs into everyday healthcare, expanding coverage through insurance and Medicare so more people can benefit from advanced, data-driven care." Transforming Health Care Through Innovation Thirty-five million users already have access to Digbi Health's personalized programs through major health plans and employers. With over $16 million in funding from leading venture capital firms, the company will further expand its reach. This Reg CF offering on StartEngine allows more individuals to support the company's groundbreaking work in bringing effective, personalized treatments for obesity and digestive health to millions. About Digbi Health Digbi Health pioneered Precision Biology, integrating gut microbiome, CGM, and genetics to holistically prevent and treat three of the top four most expensive healthcare conditions - Obesity, Cardiometabolic, and Digestive. Our innovative, proven approach is highly differentiated and resonates with employers and health plans seeking new ways to eliminate the scourge of point solutions and reduce healthcare costs, especially GLP-1-related drug costs. Our competitive edge lies in our unique data and bioinformatics platform, consolidating millions of diverse data points across genetics, progression of gut microbiome, metabolic, health, and disease markers. This repository empowers us to personalize care, unearth patentable signatures, generate impactful health risk profiles, and stratify patient care accurately for treatment. Digbi's unique contactable data set appeals to top pharmaceutical and food companies, positioning us as a leader in the field. This equity raise is being conducted in accordance with Regulation Crowdfunding (Reg CF), a provision enacted by Congress under the JOBS Act, and is fully compliant with the rules and regulations established by the U.S. Securities and Exchange Commission (SEC). For more information on the equity raise and how to invest, visit https://www.startengine.com/offering/digbi-health

Aniiket Sengar
30 September, 2024

Digbi Health Expands Its Employer Offering with the GLP-1 Obesity Management Solution Integrated Across Payer, PBM, Provider, and Employer

News Provided by Digbi Health July 22 2024 10:00 EST State Public Health Insurance Trust Partners with Digbi Health to Manage Obesity Treatment Costs Amid Rising GLP-1 Drug Expenses for its Municipal and Teachers Union Workers Mountain View, July 22, 2024 – A leading public health insurance trust has selected Digbi Health to manage the escalating costs and effective utilization of new GLP-1 weight-loss drugs. This partnership will leverage Digbi Health's proprietary Obesity Compass to provide effective and cost-efficient treatment plans for all its members. Due to the surge in demand for GLP-1 drugs, employers and health plans nationwide face uncertainty and significant cost increases. This partnership addresses these challenges by employing innovative solutions without compromising a member’s health. Key Highlights: Effective Cost Management:The initiative launched in June as a cost-containment strategy after unsustainable growth in GLP-1 medication usage and costs. Prior Authorization:Digbi Health will oversee the Prior Authorization for all weight management medications, using patented predictive modeling to determine the most effective and economical care modalities for members to achieve a healthy BMI. Holistic Solution: Digbi Health leverages genetics, gut microbiome, continuous glucose monitoring (CGM), and lab reports to provide personalized food and lifestyle support to all members on weight management medications. This approach addresses the underlying root causes of their conditions, related comorbidities, medication side effects, and, if recommended, medication tapering. Precision Biology is an innovative approach that uses an individual's genetic makeup, gut microbiome profile, and metabolic data to create highly personalized treatment plans. Precision Biology can identify the most effective dietary, lifestyle, and pharmacological interventions by analyzing a person's unique biological data. This method ensures that treatments are tailored to address the root causes of obesity and related conditions, resulting in more effective and sustainable health outcomes. “As the market struggles with finding an optimal strategy for weight management and GLP-1 cost containment, we aim to set new care standards by focusing on three key areas: enhancing member experiences through integrations, using Precision Biology to more accurately identify those who need medication support, and tackling the underlying root causes, comorbidities, and side effects. We look forward to successfully collaborating with employers, health plans, benefits consultants, and PBMs to deliver personalized, effective, and affordable care,” said Ranjan Sinha, Founder and CEO of Digbi Health. About Digbi Health: Digbi Health pioneered Precision Biology to treat obesity, T2 Diabetes, and digestive health by harnessing genetics and gut microbiome analysis. This innovative approach develops personalized "Food-As-Medicine" treatment plans, targeting the root causes of obesity and T2D. Digbi Health’s GLP Compass, developed working with Novo Nordisk and the University of Virginia Medical School, uses proprietary data and AI models to identify the most clinically effective and cost-efficient treatment paths.

Aniiket Sengar
21 July, 2024

Gulf Coast Regional Blood Center selects Digbi Health to Elevate Employee Health Programs for Weight Management, Diabetes, and Digestive Issues

Palo Alto, California, Feb 15, 2024 - Digbi Health, an innovator in personalized health technology, is proud to announce its new collaboration with Gulf Coast Regional Blood Center, a key blood provider in Houston and surrounding counties. This partnership is set to revolutionize employee health management by integrating personalized health solutions based on advanced genetics and gut biome analysis into the wellness programs of a critical healthcare provider. Enhancing Employee Wellness at Gulf Coast Regional Blood Center The Gulf Coast Regional Blood Center team will benefit from Digbi Health's comprehensive health platform to optimize weight management and mitigate physical and mental health challenges. By leveraging precision biology through detailed genetics and gut microbiome analysis, this initiative perfectly aligns with the center's dedication to fostering the health and well-being of its employees and the communities they serve. The program specifically addresses chronic conditions such as obesity, type 2 diabetes, and digestive disorders, benefiting employees and their families. A Strategic Collaboration to Enhance Community Health Digbi Health's tailored health approach is strategically aligned with the Gulf Coast Regional Blood Center’s core mission of community partnership to save and sustain lives, beginning with its workforce. This collaboration is poised to enrich the center's employee wellness program, establishing a new benchmark for employee care within the life-saving operations of the blood center. Ranjan Sinha, CEO of Digbi Health, said on the collaboration, "This partnership is a milestone for us at Digbi Health. It embodies our commitment to transform individual chronic care by decoding our genetics, gut biome, and blood markers.“ About Gulf Coast Regional Blood Center Founded in 1975, Gulf Coast Regional Blood Center is an independent, nonprofit organization committed to ensuring a safe and reliable blood supply. With over 650 employees, Gulf Coast Regional Blood Center serves a vast area across Texas, including 26 counties. About Digbi Health Digbi Health specializes in genetics, gut microbiome, and digital health technologies to redefine personalized healthcare. Their platform is designed to reduce medication dependence and healthcare costs, particularly in chronic illness management. For more information, media inquiries, or interviews, please contact: partner@digbihealth.com This contract underscores Digbi Health's commitment to expanding personalized healthcare nationwide.

Aniiket Sengar
15 March, 2024
Press Release
pin

Digbi Health Launches GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1 based Personalized Care for Obesity

PALO ALTO, Calif., September 28, 2023 – (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit™, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity.  Key Highlights: Digbi GLP-Fit™  uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications. For Pharmacy Benefit Managers (PBMs), Digbi GLP-Fit™ streamlines prior authorization processes for GLP-1 obesity management drugs, eliminating member frustration, generating multi-million dollar savings, and creating goodwill for health plans and employers. Digbi GLP-Fit™ program guarantees 100% financial ROI, providing immediate and tangible savings for employers, PBMs, and health plans, all while ensuring optimal and medically safe patient care. The Science Behind Digbi GLP-Fit(™) This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically effective obesity treatment programs. Unlike other digital programs that rely exclusively on behavior change, Digbi GLP-Fit™  is based on recognition by the National Institutes of Health (NIH)  and medical research institutions like Harvard Health that genetics account for up to 80% of the risk of obesity and that an individual's insulin resistance and gut-microbiome are essential factors in addressing obesity. Digbi GLP-Fit™ integrates telehealth and precision nutrition based on genetics, gut microbiome, and insulin metabolism. Sustainable, Effective, and High-Quality Care This personalized approach offers tremendous savings for employers and payers. Digbi's program ensures that individuals are not unnecessarily on lifelong GLP-1 treatments, aligning with Digbi Health's prevention and effective care mission. With a Google rating of 4.8 stars, Digbi Health stands out for its unwavering commitment to delivering a high-quality member experience. "We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic," said Ranjan Sinha, CEO of Digbi Health. "Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.” Novo Nordisk's Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions.   True Personalization: The 5-Point  Digbi GLP-Fit™ Program Difference While other digital providers tout personalization, Digbi GLP-Fit delivers the following advanced capabilities: Precision Diagnostics: Incorporates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) to provide a comprehensive bio-digital twin view of an individual's health. Risk Assessment: Evaluate the patient's obesity risk embedded in their genetics, gut microbiome, and insulin metabolism. Three hundred gene variants are used to develop and monitor a polygenic risk score for weight regain. Precision Biology-Based  Lifestyle Support: The FDA requires GLP drugs to have nutrition and lifestyle support. Proven and Patented De-prescription Path: Develops clinically safe,  sustainable, personalized tapering off-plan for GLP drugs. Gut Microbiome Informed Care: GLP is a gut hormone that regulates appetite, metabolism, and insulin secretion. Recent studies have shown that the gut microbiome may play a role in the effectiveness of GLP-1 drugs. With Digbi GLP-Fit™, the gut microbiome is monitored every 120 days. A longer tapering period is considered if the gut microbiome has not shifted to a less obesogenic state. Media Contact: Beverly Ibarrolan; beverly@digbihealth.com About Digbi Health Digbi Health is leading through innovation, offering a holistic solution for treating Obesity, Cardiometabolic, and Digestive disorders—three of healthcare's top 4 costly conditions. Our Precision Biology approach uses genetics, gut microbiome, Abbott CGM, and pharmaceuticals only when necessary to create personalized care programs that slash medication dependency and healthcare costs. We are on a mission to make chronic illness optional. Learn more at: www.digbihealth.com  

Ranjan Sinha
29 September, 2023
pin

Digbi Health features in the Top 10 Startups of LG’s ‘Mission for the Future’ challenge

Chosen ‘Mission for the Future’ Companies and LG to Jointly Pursue Innovative Solutions for Digital Health, the Metaverse and Electric Mobility. The LG Electronics North American Innovation Center, LG NOVA, has selected the Finalist companies for its Mission for the Future global challenge program. Representing multiple potential business paths in three industries, the companies will be working with the LG NOVA team to collaborate on new business ventures, alongside continuing to grow and scale their companies, qualifying for potential investment from LG and other investors within LG NOVA ecosystem to develop impactful solutions for people, communities and the planet.* “This inaugural year of our challenge demonstrated how effective and powerful collaboration between technology startups and established corporations can help accelerate the innovation process,” said LG Electronics Senior Vice President of Innovation Dr. Sokwoo Rhee and head of LG NOVA. “Congratulations to the Finalists and all the companies that participated in the Mission for the Future challenge. We look forward to the journey with these companies innovating for a brighter, more technologically advanced future.” The finalists were selected from an initial pool of approximately 1,300 applicants. They secured the top spot after working closely with the LG NOVA Entrepreneur-In-Residence team over a six- to nine-month period to build and test the proposals. Throughout the process, the companies had opportunities to meet with LG business teams and other investors within the LG NOVA ecosystem. Finalists were presented to LG Electronics Global CEO William Cho. This unique challenge program, which has the opportunity to diversify and expand LG’s technology portfolio, prioritizes innovating for a better life across key impact industries, according to Rhee. “These incredible companies hold the potential of changing the world, and LG looks forward to collaborating with them to leverage innovation to impact society in meaningful ways,” he said. With this selection of companies, LG NOVA will build new businesses in Digital Health, Electric Mobility and the Metaverse and pursue multiple paths to deliver new services and solutions that will help us move forward faster into the future. Digital Health – With digital health capabilities key to enabling the delivery of healthcare to diverse and disparate communities, LG NOVA is working to expand and scale greater access to healthcare and personal health services. Digbi Health: is a digital care platform to prevent and reverse chronic metabolic, digestive and mental health conditions using gut microbiome insight, genetics, AI and food-as-medicine. Together LG and Digbi will work to make care globally accessible at home and the office, and to advance cure. LifeNome: is a B2B2C precision health platform powered by genomics and AI, offering personalized health and well-being solutions to the world's leading enterprises. LG and LifeNome plan to bring to market the world’s first precision maternal and family health platform, supporting pregnant individuals 24/7 from conception all the way to the early stages of a child's life. Mindset Medical: is a sensor-based technology platform that can use a camera in patient-owned devices to virtually capture health and biological readings to assist doctors in enhancing medical diagnosis and treatment effectiveness. Expanding upon new services available to doctors and providers, LG’s work with Mindset Medical is expected to make it easier for medical providers to understand patient health over time or during live virtual doctor visits. XRHealth: develops virtual treatment rooms, integrating immersive VR/AR technology, licensed clinicians and real-time data analytics on one platform, providing a comprehensive therapeutic care solution for patients through the continuum of care, from the hospital to the patient’s home. LG and XRHealth will continue to grow the service offering to deliver more insights to clinicians and enable more precise personalized care. Electric Mobility – With LG’s commitment to sustainability as an organization, LG NOVA is working to pursue new opportunities to expand access to electric vehicle (EV) and electric mobility solutions by enabling more businesses to leverage their infrastructure to provide EV services. Driivz: empowers major EV service providers with an end-to-end EV charging and smart energy management software platform. LG and Driivz will work together to enable the hospitality industry across the United States to offer EV charging-as-a-service, while optimizing their EV charging operations and providing their customers with an exceptional EV charging experience. I-EMS Solutions, Ltd. uses innovative AI and blockchain-based distributed energy resource management systems (DERMS) and transactive energy software platforms to enable power optimization across smart cities, smart homes, and e-mobility. By working with I-EMS, LG will help modernize the electricity grid and optimize energy management to deliver better power management solutions for the market. SparkCharge: offers an affordable and convenient way for electric vehicle owners to charge their EVs without a direct-access charger at home or on the road. LG and SparkCharge plan to work together to deliver turnkey EV solutions for businesses to create a stream of revenue from their parking spaces. The Metaverse – The Metaverse will bring greater capabilities that will change how we engage across the digital space in the future. LG is looking to broaden its role and explore new services and applications for enterprises that leverage the capabilities of the Metaverse. iQ3 Connect: provides immersive 3D workspace technology to enable distributed teams to cost-effectively work, collaborate and train from anywhere, on any AR, VR, or 2D device. LG will work with iQ3 Connect to deploy immersive training and realtime collaborative workspace solutions for enterprises. NeuroTrainer: is a brain training and optimization platform deployed in VR to create immersive environments and training protocols that utilizes the scientific principles of neuroplasticity to enhance focus and cognitive performance. Expanding upon iQ3 capabilities, LG and NeuroTrainer will work together to add platform capabilities and enhancements designed to further refine NeuroTrainer as a powerful tool for corporate wellness and mental resiliency. LG NOVA’s second annual Mission for The Future (2022) is now open for submissions. Deadline to submit is Thursday, Oct. 6, 2022. Please visit www.lgnova.com/mission22 for more information on how to submit new ideas to LG NOVA. *Subject to due diligence and other considerations. # # # About LG NOVA LG NOVA, the North American Innovation Center for global innovation leader LG Electronics, is a team focused on bringing innovation from the outside to LG. LG NOVA is based in Santa Clara, Calif. The center's mission is to build, nurture and grow innovations that impact the future. Learn more about LG NOVA at www.lgnova.com. About LG Electronics USA: LG Electronics USA, Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics, Inc., a $63 billion global innovator in technology and manufacturing. In the United States, LG sells a wide range of innovative home appliances, home entertainment products, commercial displays, air conditioning systems, energy solutions and vehicle components. LG is 2022 ENERGY STAR® Partner of the Year-Sustained Excellence. The company’s commitment to environmental sustainability and its “Life’s Good” marketing theme encompass how LG is dedicated to people’s happiness by exceeding expectations today and tomorrow.

Aniiket Sengar
07 September, 2022
pin

Novo Nordisk to explore obesity risk tests with Digbi Health pilot project

Novo Nordisk will begin a pilot project to evaluate how genomic and microbiome-based tests can be used to help prevent obesity. The work is part of a tie-up with Digbi Health and comes as Novo’s Wegovy franchise is expected to keep up its quick growth. The obesity medication was approved in June 2021. Earlier this year, the drugmaker doubled its revenue target for Wegovy, saying it expects to bring in more than $3.7 billion in sales by 2025. By working with Digbi and the startup’s digital screening offerings, the pilot will explore how a person’s genes, proteins, gut bacteria and lifestyle data can help predict whether they have a high or low risk of obesity as well as the range of cardiac and metabolic conditions that may come with it. Obesity-related risks vary significantly by gender and ancestry, and, according to the companies, most weight management programs do not incorporate information from genetics or the gut microbiome. As part of the pilot, Digbi—which offers diagnostic tests and artificial-intelligence-powered coaching programs—has enrolled in Novo Nordisk’s Global Prevention Accelerator Program, which launched last year with a special focus on worldwide obesity. With funding from the Big Pharma, Digbi aims to show its digital care offerings can scale up to reach large numbers of people while also being adaptable for local populations. The companies said they plan to complete the initial steps of the pilot by the end of September before expanding Digbi’s platform to demonstrate large-scale validation through the help of Digbi’s user base. Novo’s accelerator had previously selected Ksana Health, developer of the remote measurement platform Vira, to offer an objective system for tracking behavior patterns and forming personalized care plans. The Danish drugmaker also expanded its research into obesity this year through a collaboration with EraCal Therapeutics, a Swiss biotech that is developing new treatments aimed at food intake regulation, suppressing appetite and other characteristics of metabolism. Also known as semaglutide, Novo Nordisk’s Wegovy was first approved for treating diabetes. It received a new green light in obesity alongside diet and exercise last year based on phase 3 trial data showing it helped one-third of treated patients lose more than 20% of their body weight over about a year and a half. Patients without Type 2 diabetes lost 17% to 18% of their weight on average.

Aniiket Sengar
22 August, 2022
pin

Virgin Pulse expands curated ecosystem with Digbi Health to address rising health and wellbeing needs

Clients and their members have integrated access to more solutions supporting areas including caregiver support, digestive health, sleep habits, and financial wellbeing. Providence, R.I., July 13, 2022 – Virgin Pulse, the leading global digital-first health and wellbeing company, today announced the addition of five new partners to its ecosystem, providing more access to areas of growing importance for clients and users, including caregiver support, digestive health, sleep habits, and financial wellbeing. Virgin Pulse’s partner ecosystem streamlines access to more than 70 specialty solutions, making it easy for companies to connect members with a broad range of high-impact health and wellbeing programs. The following five partners are joining the Virgin Pulse partner ecosystem: Cariloop – Caregiver support Digbi Health – Digestive health Fidelity Investments – Financial wellbeing (international/non-US) SleepFit – Adult sleep improvement SleepWellBaby – Infant parenting support Human resources and benefits leaders have more options than ever, with over 350,000 health-related apps now available via app stores.* Careful vetting is necessary to determine which programs are most effective, engaging, and secure. Virgin Pulse’s comprehensive review process ensures each partner within its ecosystem maintains the highest privacy and security standards, drives member engagement, and is focused on delivering health and cost-savings outcomes. Virgin Pulse eliminates administrative burdens by completing these comprehensive reviews of all new partners along with handling vendor contracting, procurement, and billing on behalf of clients. “We’re continuously striving to expand our partner ecosystem with solutions that address issues of greatest interest for our clients and users,” said Winston Ball, vice president, partner ecosystem at Virgin Pulse. “These latest additions are reflective of some of the top trends in health. For example, digestive diseases are one of the most prevalent causes of disability in the workforce, with 20 million Americans suffering from chronic digestive diseases.** We are in the best position to increase awareness, access, and utilization of these specialty partners and get them in the hands of those who will benefit the most.” Diverse and Customizable Partner Ecosystem Virgin Pulse’s partner ecosystem helps companies close gaps in care across more than 20 health and wellbeing categories while addressing the most common and costly health concerns. To optimize program utilization and user experience, all partner solutions are seamlessly integrated and accessible through Virgin Pulse’s Homebase for Health® experience, which provides a single entry point to comprehensive digital capabilities and live services, as well as the partner ecosystem. Combined with personalized recommendations and incentives, the platform guides members to make the best possible decisions at every stage of their health and wellbeing journey. Usage data shows that four times more members are engaged with select partner solutions integrated into Virgin Pulse versus standalone deployments. Virgin Pulse also offers its one-contract VP+ partner bundle program, which enables employers and health plans to easily curate a suite of pre-vetted, pre-integrated partner solutions that meet the needs of their populations. More information about the new partners joining the Virgin Pulse partner ecosystem: Caregiver Support: Cariloop To ensure that no one goes through caregiving alone, Cariloop is arming families with the world’s first human-powered Caregiver Support Platform. Creating a seamless balance of human touch and tech, Cariloop pairs families with a licensed or certified Care Coach through its cloud-based platform to help them plan for and manage every aspect of their journey of caring for loved ones. Fueled by the core values of Service, Empathy, Innovation, and Integrity, Cariloop’s mission is to help relieve stress and anxiety felt by all caregivers. Digestive Health: Digbi Health Digbi Health provides convenient virtual care to people living with polychronic conditions associated with gastrointestinal and cardiometabolic illnesses. Digbi uses AI to harness genetic, gut microbiome, clinical, lifestyle, and behavioral signals to deliver tailored whole-person care, which includes food as medicine, behavioral coaching support, remote monitoring, and MD-connected care coordination to equitably target the root cause of illness. Financial Wellbeing (international/non-US): Fidelity Investments Fidelity’s mission has remained the same since their founding as a privately-held company over 75 years ago: to strengthen the financial well-being of their clients. Fidelity helps people invest and plan for their future, and supports companies to deliver benefits to their employees. Fidelity’s global financial wellness solution is a customizable, internationally-applicable digital platform across multiple languages, aimed at improving employees’ knowledge and confidence around personal finances, enabling informed decisions to improve financial outcomes, and providing employers with powerful insights to elevate strategy. Adult Sleep Improvement: Sleepfit Sleepfit is an evidence-based digital sleep solution that uses science and the knowledge of sleep experts to ensure adults get the sleep they need. It is designed to boost performance, safety, and wellbeing through sleep awareness, sleep disorder screening, and kick-starting healthy sleep habits. Sleepfit works with innovative employers and insurers to provide scalable, affordable, and measurable sleep improvement programs. Sleepfit’s digital program lowers healthcare costs, increases employees’ productivity, and improves the individual’s quality of life. Infant Parenting Support: SleepWellBaby SleepWellBaby is the baby-led sleep and settling app that empowers parents to be their child’s sleep expert, while providing critical mental health support for parents. We translate cutting-edge research and a proven approach that helps more than 60,000 babies and toddlers every year. SleepWellBaby delivers evidence-based parenting advice and tools on baby sleep and settling to parents with children 0-3 years old to improve child health outcomes, reduce parental mental health issues, and shorten the return-to-work period.

Aniiket Sengar
13 July, 2022
pin

Digbi Health enhances mental health and chronic care by adding Ethnic-relevant genetic markers

Digbi Health incorporates ethnic-relevant genetic risk scores to personalize care for metabolic and mental health conditions associated with gut and obesity. The new panel will improve health equity and outcomes for ethnically diverse workforces. Digbi Health announced today they are incorporating ethnic-specific risk scores for nutrition, fitness, obesity, diabetes, hypertension, mental and digestive health across its virtual care program for people living with polychronic physical and mental illness associated with inflammatory gut and weight. It’s well established that the risk of illness, food allergies, gut microbiome composition and pharmaceutical risk varies significantly by ethnicity and gender because they are rooted in an individual's genetics and gut microbiome. For example, A) African Americans have a higher genetic risk for hypertension and lung cancer despite lower smoking rates, B) black women are more likely to get breast cancer, C) Hispanic adults have higher risks of diabetes. D) Asian Indian men have four times higher risk of cardiovascular disease even if with a normal BMI, non-smoking and vegetarian E) white European males have a higher risk of Atrial Fibrillation, F) Jews of European descent have one of the highest risks of developing colon cancer compared to any ethnicity worldwide and, G) white women have a higher risk of a digestive and inflammatory disease like arthritis. Genetic testing has become increasingly widespread, with millions of Americans conducting genetic tests at home. Employers and health plans are embracing digital care programs for their employees. Current genetic tests and digital care programs fail to account for gender and ethnic diversity despite the popularity. Specifically, 78% of genetic studies come from people of predominantly European descent, and most digital care guidelines are primarily based on studies done with the white male population, even though they only make up 16% of the population, resulting in significant inequity in care outcomes for women and people of color. Digbi’s new genetic scores address these health outcome inequities by personalizing care using the member’s ethnic ancestry, measured by their DNA sequence, gut microbiome, food habits, and food preference. In a recently published study of 393 adults, Digbi’s polychronic care program proved to be equally effective across ethnicities and income levels. “It’s extremely problematic for the health of an increasingly diverse workforce to limit genetic, gut microbiome data to one population and one-size-fits-all digital care programs that have a proven bias towards one gender and ethnicity. Digbi’s science and care team is committed to eliminating health outcome disparities while advancing our understanding of genetic and gut microbiome science,” said Ranjan Sinha, Founder and Chief Executive Officer of Digbi Health. About Digbi Health Digbi Health provides convenient, virtual care to people living with polychronic physical and mental illness associated with inflammatory gut and weight. Digbi uses AI to harness genetic, gut microbiome, clinical, food information, and behavioral signals, to deliver tailored whole-person care, which includes food as medicine, behavioral coaching support, remote monitoring, and MD connected care coordination to equitably target the root cause of illness. Follow us on LinkedIn, Twitter, Instagram, and Facebook.

Aniiket Sengar
18 January, 2022
pin

Commercial creamery employees and dependents granted full access to Digbi health preventative care

Digbi Health, an AI-powered, precision digital therapeutics platform that uses gut microbiome and host genetic information, proudly announces that its preventative care platform will be widely available to all Commercial Creamery employees and dependents. Aimed at reducing polychronic illnesses by healing the gut, Digbi Health uses artificial intelligence (AI) technology to create personalized nutrition and exercise plans based on an individual’s unique genetic makeup to tackle obesity and common comorbidities like IBS, acid reflux, diabetes and musculoskeletal pain. Digbi also offers mental health support targeted at reducing headaches, migraines, anxiety, depression and insomnia - all of which are rampant among the workforce. Employers care about their employees health as it’s not secret health is paramount to workplace productivity and employee happiness. As mental and physical illnesses continue to rise in the workplace, employers are yearning for innovative benefit plans that provide individualized care to each employee. Digbi Health provides employers with cutting-edge benefit plans that are both preventive and holistic, meeting each member exactly where they are at and what they are willing to do. Commercial Creamery is proud to offer Digbi Health to all of its employees, spouses and covered dependents 18 and older. Digibi Health generates compelling clinical grade outcomes that reduce polychronic disease symptoms. The program also offers therapy tools and support through the Digbi app and empowers members to take control of their mental health through food, prebiotics, lifestyle and data insights. Seventy two percent of Digbi Health participants saw an 8.92 percent average weight loss as well as improvement in blood sugar levels, anxiety/depression, acid reflux, IBS, chronic pain, skin issues and more -- all issues stemming from gut imbalances. About Digbi Health Available on the wellness navigation platform of a large health plan in California, Digbi Cares™ is a next-generation, prescription-grade digital therapeutic platform, polychronic mental and physical illness. We use artificial intelligence (AI) to analyze genetics, gut bacteria, lifestyle habits, socioeconomic and behavioral risk patterns to create evidence-based personalized nutrition, fitness, sleep, and stress management programs. It is proven to reverse obesity, improve mental health and reduce inflammatory gut, musculoskeletal, cardiovascular, and insulin-related illnesses.

Aniiket Sengar
29 October, 2021

Contact Us

Have any questions? Please feel free
to reach out and contact us

Email

Powered by science

We know why you’re here. You saw the word “science” and your heart took a little extra beat, didn’t it? you’re the patient who prints out articles to take to your doctor’s office. You scour the latest studies for the newest developments in nutrition, weight loss, and fitness.